药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Etidronic acid
Fluprednisolone
The risk or severity of adverse effects can be increased when Aldosterone is combined with Fluprednisolone.
Etidronic acid
Tixocortol
The risk or severity of adverse effects can be increased when Aldosterone is combined with Tixocortol.
Etidronic acid
Fluprednidene
The risk or severity of adverse effects can be increased when Aldosterone is combined with Fluprednidene.
Etidronic acid
Fluticasone furoate
The risk or severity of adverse effects can be increased when Aldosterone is combined with Fluticasone furoate.
Etidronic acid
Ciclesonide
The risk or severity of adverse effects can be increased when Ciclesonide is combined with Aldosterone.
Etidronic acid
Paramethasone
The risk or severity of adverse effects can be increased when Paramethasone is combined with Aldosterone.
Etidronic acid
Cortisone acetate
The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Aldosterone.
Etidronic acid
Corticotropin
The risk or severity of adverse effects can be increased when Corticotropin is combined with Aldosterone.
Etidronic acid
Idelalisib
The risk or severity of adverse effects can be increased when Aldosterone is combined with Idelalisib.
Etidronic acid
Brentuximab vedotin
The risk or severity of adverse effects can be increased when Aldosterone is combined with Brentuximab vedotin.
Etidronic acid
Emapalumab
The risk or severity of adverse effects can be increased when Aldosterone is combined with Emapalumab.
Etidronic acid
Siponimod
The risk or severity of adverse effects can be increased when Aldosterone is combined with Siponimod.
Etidronic acid
Ibrutinib
The risk or severity of adverse effects can be increased when Aldosterone is combined with Ibrutinib.
Etidronic acid
Siltuximab
The risk or severity of adverse effects can be increased when Aldosterone is combined with Siltuximab.
Etidronic acid
Secukinumab
The risk or severity of adverse effects can be increased when Aldosterone is combined with Secukinumab.
Etidronic acid
Certolizumab pegol
The risk or severity of adverse effects can be increased when Aldosterone is combined with Certolizumab pegol.
Etidronic acid
Golimumab
The risk or severity of adverse effects can be increased when Aldosterone is combined with Golimumab.
Etidronic acid
Rilonacept
The risk or severity of adverse effects can be increased when Aldosterone is combined with Rilonacept.
Etidronic acid
Tocilizumab
The risk or severity of adverse effects can be increased when Aldosterone is combined with Tocilizumab.
Etidronic acid
Canakinumab
The risk or severity of adverse effects can be increased when Aldosterone is combined with Canakinumab.